Last update 21 Nov 2024

Ethynodiol diacetate/mestranol

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

OVULEN-21, OVULEN-28, Ovulen

Target

Mechanism

PR agonists(Progesterone receptor agonists)

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Viatris Holdings LLC

Active Organization-

Inactive Organization

Viatris Holdings LLC

Drug Highest PhaseWithdrawn

First Approval Date

US (23 Mar 1966)

Regulation-

Structure

Molecular FormulaC21H26O2

InChIKeyIMSSROKUHAOUJS-MJCUULBUSA-N

CAS Registry72-33-3

View All Structures (2)

100 Clinical Results associated with Ethynodiol diacetate/mestranol

100 Translational Medicine associated with Ethynodiol diacetate/mestranol

100 Patents (Medical) associated with Ethynodiol diacetate/mestranol

Literatures (Medical) associated with Ethynodiol diacetate/mestranol

01 Jul 1984·Journal of the Royal Society of MedicineQ3 · MEDICINE

Exogenous Hormones in the Aetiology of Cancer in Women

Q3 · MEDICINE

Review

Author: Vessey, M P

Both animal experimental work and epidemiological clinical and laboratory research on the effects of endogenous hormones in the human have made it clear that some influence of administered female sex hormones on the risk of certain cancers would be anticipated and this has turned out to be the case. This review focuses on the administration of hormones during pregnancy around the time of the menopause and to prevent pregnancy. In the daughters who were exposed in utero to stilbestrol during the 1950s and 1960s the most important effect is the development of clear cell adenocarcinoma of the vagina or cervix. Few cases of this disease have been reported before puberty but the cumulative risk thereafter up to the age of 24 years is estimated to be between 1.4 and 4/10000 exposed. Much less attention has been paid to the mothers who actually took the stilbestrol than to their daughters but the published data fail to provide any convincing evidence of an increased risk of either breast or reporductive cancer among them. Regarding the administration of hormones around the time of menopause it is well established that unopposed estrogen therapy in menopausal women can cause endometrial cancer. This has been demonstrated in a large number of case control studies reported since 1975. Most of these studies were conducted in the US and most concern the drup Premarin (conjugated equine estrogens). Some cohort studies also have been reported and they largely support the results of the case control studies. There is now little doubt that combined oral contraceptives (OCs) protect against both epithelial ovarian cancer and endometrial cancer. Preliminary findings in the major cohort studies concerned with the longterm effects of OC use also are encouraging. A series of large case control studies conducted during the 1970s showed clearly that there is no general association between oral contraceptive use and breast cancer risk but these large studies included few women with appreciable OC use at an early age and accordingly the publication by Pike et al. in 1981 caused much concern. Pikes study involved 163 women in Los Angeles County in whom breast cancer has been diagnosed at age 32 or less together with a like number of neighborhood controls. Vessey et al. (1982) and the Centers for Disease control subsequently published results which did not support the California findings. Preliminary results from a new case control study conducted in Oxford and in London since 1980 suggest an increased risk of breast cancer in young women who have prolonged OC use before 1st pregnancy. The situation is very confusing and it may be some time before there is a conclusive answer. In a large cohort study conducted in Los Angeles rates of progression from cervical dysplasia to carcinoma in situ were much higher in women using Ovulen than in women using IUDs.

01 Dec 1983·The LancetQ1 · MEDICINE

PROGESTAGEN "POTENCY" AND BREAST CANCER

Q1 · MEDICINE

Letter

Author: Swyer, G.I.M.

The validity of the table of oral contraceptive (OC) formulations ranked according to their progestagen potency by Pike et al. and of the table derived from this and published by the Committee on Safety of Medicines is refuted. It is noted that the delay of menses test used by Pike relates only to endometrial hemostatic efficacy and provides no evidence for ranking synthetic progestagens and by any other property. Moreover even if this criterion is used only those formulations containing 50 mcg ethinyl estradiol and the progestagens norethisterone norethisterone acetate ethynodiol diacetate norgestrel and levonorgestrel can be compared. Acceptable data do not exist for the rest of the formulations. There are only 12 OC formulations (Eugynon 50 Ovran Neogynon Neogynon ED Ovulen 50 Anovlar 21 WY 125 D/50 Gynovlar 21 Norlestrin Minovlar Minovlar ED and Orlest 21) for which potency ratios can theoretically be deduced from the delay of menses data for mixtures containing 50 mcg ethinyl estradiol.

01 Dec 1983·The American Journal of the Medical SciencesQ4 · MEDICINE

Case Report: Familial Central Diabetes Insipidus: Vasopressin and Nicotine Stimulated Neurophysin Deficiency with Subnormal Oxytocin and Estrogen Stimulated Neurophysin

Q4 · MEDICINE

Article

Author: Piers R. Blackett ; Dale H. Altmiller ; Alan G. Robinson ; Said M. Seif

Five members of a family with dominantly inherited diabetes insipidus were diagnosed and treated with deamino-d-arginine vasopressin (DDAVP), a vasopressin analogue given intranasally. All subjects demonstrated subnormal levels of arginine vasopressin (AVP) by radioimmunoassay in response to cigarette smoke inhalation, a standardized nicotine stimulation test. Levels of oxytocin (OT) were found to be normal and unstimulated after cigarette inhalation in two subjects, but when two affected male siblings ingested Ovulen, OT and ESN were stimulated to subnormal levels. After twelve months of DDAVP treatment, the low AVP response to nicotine was preserved whereas the carrier protein, nicotine stimulated neurophysin (NSN) remained undetectable.

100 Deals associated with Ethynodiol diacetate/mestranol

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Ethynodiol diacetate/mestranol

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation